Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Adaptimmune Therapeutics plc
ADAP | US
0.82
USD-0.02
-2.24%
ADAP | US
About Adaptimmune Therapeutics plc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
0.82
Open
0.84
High
0.85
Low
0.82
Adaptimmune Therapeutics plc a clinical-stage biopharmaceutical company provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck and urothelial cancers. The company has strategic collaboration and license agreement with Genentech Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon the United Kingdom.
View LessADAP | US
Risk
56.8
Sharpe
0.27
Luna's Score
48/100
Recommendation
Hold
Luna says (ADAP | US)
What's Working
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
25.3%1 month
56.8%3 months
73.6%6 months
79.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.24
Debt to equity
0.49
Debt to assets
0.15
Ent. to EBITDA
-1.71
Ent. to rev.
0.34
PEG
0.11
Other Fundamentals
EBITDA
-72.88M
MarketCap
210.68M
MarketCap(USD)
210.68M
Div. yield
-
Op. margin
53.58
Erngs. growth
-
Rev. growth
2.40K
Ret. on equity
-65.04
Short ratio
5.92
Short perc.
3.57
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.14
Range1M
0.19
Range3M
0.66
Volumes: Market Activity
Rel. volume
0.89
Price X volume
793.43K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.71 | - | Cheaper |
| Ent. to Revenue | 0.34 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.24 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 73.58 | - | Par |
| Debt to Equity | 0.49 | -1.23 | Expensive |
| Debt to Assets | 0.15 | 0.25 | Cheaper |
| Market Cap | 210.68M | - | Emerging |
